Why Cancers Caused by BRCA Mutations Recur
Researchers at the University of Pennsylvania’s Basser Center for BRCA at the Abramson Cancer Center have discovered factors that may make breast and ovarian cancers associated with BRCA1/2 gene...
View Article$3.5 Million Grant to Improve Cervical Cancer Care in Botswana
Penn Medicine experts have worked with local partners to improve health care in Botswana for years. A new $3.5 million grant from the NCI will help further that work by addressing one of Botswana’s...
View ArticleCareConnect Lowers Opioid Use Disorder Treatment Barriers
Fifty-five percent of CareConnect’s patients had an active buprenorphine prescription for treatment a month after first engaging with the program.
View ArticleDeeply Rooted Program Awards 22 ‘Community Green Grants’
To increase community-based nature initiatives and improve health in Black and brown Philadelphia neighborhoods, Penn Medicine and CHOP’s Deeply Rooted Collaborative launched a Community Green Grants...
View ArticleCAR T Cell Therapy Reaches Beyond Cancer
Penn Medicine researchers laud early results for CAR T therapy in a small set of patients with the autoimmune disease lupus.
View ArticlePenn Develops mRNA Flu Vaccine
An experimental mRNA-based vaccine against all 20 known subtypes of influenza virus provided broad protection from otherwise lethal flu strains in initial tests, potentially serving as a general...
View ArticlePPMC Chief Nursing Officer Named UPHS Chief Nurse Executive
Longtime Penn Presbyterian Medical Center Chief Nursing Officer, James Ballinghoff, DNP, MBA, RN, has been named University of Pennsylvania Health System Chief Nurse Executive.
View ArticleA Peek of How Ketamine Acts as ‘Switch’ in the Brain
Ketamine, an established anesthetic and increasingly popular antidepressant, dramatically reorganizes activity in the brain, as if a switch had been flipped on its active circuits, according to a new...
View ArticleAwards & Accolades: November 2022
Learn how Penn clinicians and researchers are being honored by their peers.
View ArticleAI Enables the Largest Brain Tumor Study To-Date, Led by Penn
Penn led the largest-to-date global effort to identify and predict GBM tumor boundaries without compromising patient privacy.
View ArticleAbandoned House Repairs Reduced Nearby Gun Violence
Installing working windows and doors, cleaning trash, and weeding at abandoned houses led to improvements in safety, according to Penn researchers.
View ArticleStudy Shows Promise of New Anti-KRAS Drug for Pancreatic Cancer
A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, a...
View ArticleHarris Philanthropies Funds Fellowship and Pathway Equity Efforts
A gift of over $1 million to the Perelman School of Medicine from Harris Philanthropies will bolster efforts to recruit applicants from diverse backgrounds to Penn’s pathway and fellowship programs in...
View ArticlePenn Medicine at the 2022 ASH Meeting
Researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania are presenting data on the latest advances in blood cancer research and treatment at the...
View ArticleAdvance in Re-Treatment with CAR T Therapy
Penn Medicine researchers presented preliminary results from an ongoing clinical trial demonstrating successful re-treatment with CAR T cell therapy at the 2022 ASH Annual Meeting.
View ArticleNovel Drug Shows Early Promise in Treating Multiple Myeloma
A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma, a form of bone marrow cancer, in a study presented at the 2022 ASH Annual Meeting by Penn...
View ArticleGut Microbes Can Boost the Motivation to Exercise
A new study shows that some species of gut-dwelling bacteria activate nerves in the gut to promote the desire to exercise, and reveals the gut-to-brain pathway that explains why some bacteria boost...
View ArticleFDA Approves “Glowing Tumor” Imaging Drug for Lung Cancer Surgery
The U.S. FDA has approved the “glowing tumor” targeted imaging agent Cytalux (pafolacianine) for use in lung cancer surgery, following extensive clinical testing led by Penn Medicine surgeons and...
View ArticlePenn Medicine Launches New Center for Living Donation
The Penn Transplant Institute at Penn Medicine has opened a new Center for Living Donation which will expand Penn’s exceptional care for living donors, helping to maximize the number of lives saved...
View ArticlePenn Medicine Invests in Future Nurses with ASPIRE Program
Penn Medicine has partnered with the Howley Foundation and La Salle University to launch the ASPIRE Program at the Hospital of the University of Pennsylvania (HUP), marking an important investment in...
View Article